Delving into the Latest Updates on Urazamide with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Recover

Target-

Action-

Mechanism-

Therapeutic Areas

Digestive System Disorders

Active Indication

Liver Diseases

Inactive Indication-

Originator Organization-

Active Organization-

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC9H14N6O6

InChIKeyJGRWIMRUWDIMOX-DKWTVANSSA-N

CAS Registry34879-34-0

This study evaluates a cross sectional, severity stepped, evidence-based care model for patients with mental disorders (RECOVER).
RECOVER is a consortium of well-known institutions for the treatment and integrated care of patients with mental disorders, patient associations, relative associations, research institutions, health care insurances and authorities from the care region Hamburg, Germany.
This project aims to evaluate the RECOVER care model with treatment as usual (TAU) regarding cost-effectiveness (costs, efficiency and cost utility) for patients with mental disorders.
The following questions are examined:
Does RECOVER reduce psychiatric health care costs compared to TAU?
Does RECOVER improve patient relevant outcomes (i.e. symptom remission, response, daily functioning and quality of life)?
Is RECOVER cost effective compared to TAU? (from a payer's and societal perspective)
A total sample of 890 patients with mental disorders will be assessed at baseline (before treatment) and randomized into the RECOVER care model or get TAU. Follow-up assessments are conducted after 6 month and 12 month.
As primary outcomes, cost reduction, improvement in symptoms (i.e. amount of remission and response to treatment, daily functioning and quality of life) and cost-efficiency-ratios will be measured. In addition, several secondary outcome parameters will be assessed.
Impact: The present randomized controlled trial (RCT) evaluates the cross-sectional, severity stepped, evidence-based approach of the RECOVER model in patients with mental disorders. With its focus on effectiveness and cost-effectiveness, the study aims to improve the health care system in Germany.

Start Date15 Mar 2018

Sponsor / Collaborator

Universitätsklinikum Hamburg-Eppendorf

[+15]

100 Clinical Results associated with Urazamide

Login to view more data

100 Translational Medicine associated with Urazamide

Login to view more data

100 Patents (Medical) associated with Urazamide

Login to view more data

5

Literatures (Medical) associated with Urazamide

01 Mar 2017·Archives of Pharmacal ResearchQ3 · MEDICINE

Determination of urazamide in pharmaceutical preparation with room temperature ionic liquid

Q3 · MEDICINE

Article

Author: Han, Sang Beom ; Choi, Yusung ; Truong, Quoc-Ky ; Seo, Narae ; Chung, Hyun Kyu ; Kim, Byeonghee ; Park, Hyun Sun ; Lee, Jae-Yong ; Kim, Kyeong Ho ; Lee, Yoo Rim

A high performance liquid chromatographic method was developed and validated for the determination of urazamide in pharmaceutical preparation with novel green aqueous mobile phase modified with room temperature ionic liquids (RTILs). 1-Ethyl-3-methyl-imidazolium tetrafluoroborate ([EMIM][BF4]) was selected as a mobile phase additive to improve retention and avoid baseline disturbances at t₀. Various mobile phase parameters such as cation moiety, chaotropic anion moiety, pH and concentration of RTILs were optimized to determine urazamide at the proper retention time. The assay was validated according to International Conference on Harmonization guidelines. The linearity of the calibration curve was good (r² > 0.999). Intra-day precision varied between 0.50 and 1.23%. Relative standard deviations of inter-day precision ranged between 1.07 and 1.66%. Recoveries in tablets ranged between 99.7 and 101.2% and it was successfully applied to determine urazamide in pharmaceutical preparations.

Clinica Terapeutica (Rome)

Clinical study of a new hepatotropic drug, 4-amino-5-imidazolecarboxamide ureidosuccinate, using a double blind cross-over design

Author: Ripamonti, Carla

As determined by patient subjectivity and by organ-function tests, 4-amino-5-imidazolecarboxamide ureidosuccinate (I) [34879-34-0] (800 mg/day for 35 days) stimulated liver regeneration in female patients with drug- and alcohol-induced hepatic necrosis.I contains in its mol. the moieties of both ureidosuccinic acid and 4-amino-5-imidazolecarboxamide, which are known to be precursors of pyrimidine-type and purine-type, resp., nucleotides.

Drugs under Experimental and Clinical Research

Protective action of the precursors of purine and pyrimidine nucleotides in experimental poisoning by alfa-amanitin

Author: Giovannini, L. ; Romano Maltinti, M. R. ; Greco, R. ; Bertelli, A. A. E.

The toxic effects of α-amanitin (I) [23109-05-9] injections in mice were prevented by pretreatment with carbaica (II) [34879-34-0].Wherein, mice treated with I (1 mg/kg, i.p.) showed 100% mortality over 72 h after the injection.The mice given II before the I injection showed, over the same time, 30-40% survival depending on the quantity of the drug administered.The serum glutamic-pyruvic transaminase [9000-86-6] and glutamic-oxalacetic transaminase [9000-97-9] of poisoned animals were greatly reduced in those treated with II.The higher the dose of II, the greater the reduction in enzyme activity.

100 Deals associated with Urazamide

Login to view more data